☰

Mohamad Shebley, Ph.D. - Publications

Affiliations: 
2007 University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Pharmacology
Tree Info Similar researchers PubMed Report error

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Polepally AR, Ng JW, Salem AH, Dufek MB, Parikh A, Carter DC, Kamradt K, Mostafa NM, Shebley M. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist. Journal of Clinical Pharmacology. PMID 33045114 DOI: 10.1002/Jcph.1689  0.385
2019 Chiney MS, Ng J, Gibbs JP, Shebley M. Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics. PMID 31713224 DOI: 10.1007/S40262-019-00833-6  0.409
2018 Mukherjee D, Zha J, Menon RM, Shebley M. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. Journal of Pharmacokinetics and Pharmacodynamics. PMID 29427135 DOI: 10.1007/S10928-018-9574-0  0.325
2017 Shebley M, Liu J, Kavetskaia O, Sydor J, de Morais SM, Fischer V, Nijsen MJ, Bow DA. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus 3-Direct Acting Antiviral (3D) Regimen: Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 28483778 DOI: 10.1124/Dmd.116.074518  0.419
2017 Freise KJ, Shebley M, Salem AH. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. Journal of Clinical Pharmacology. PMID 28052338 DOI: 10.1002/Jcph.858  0.326
2017 Kikuchi R, Shebley M, Bow DAJ, Carr RA, Nijsen M, Morais SMd. In vitro characterization of drug metabolizing enzymes and transporters to enable a mechanistic drug-drug interaction assessment for venetoclax Drug Metabolism and Pharmacokinetics. 32. DOI: 10.1016/J.Dmpk.2016.10.212  0.329
2014 Einolf HJ, Chen L, Fahmi OA, Gibson CR, Obach RS, Shebley M, Silva J, Sinz MW, Unadkat JD, Zhang L, Zhao P. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clinical Pharmacology and Therapeutics. 95: 179-88. PMID 23995268 DOI: 10.1038/Clpt.2013.170  0.335
2009 Shebley M, Kent UM, Ballou DP, Hollenberg PF. Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: Effects on substrate binding, electron transfer, and uncoupling Drug Metabolism and Disposition. 37: 745-752. PMID 19144770 DOI: 10.1124/Dmd.108.024661  0.624
2007 Shebley M, Hollenberg PF. Mutation of a single residue (K262R) in P450 2B6 leads to loss of mechanism-based inactivation by phencyclidine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 1365-71. PMID 17460030 DOI: 10.1124/Dmd.107.014985  0.658
2006 Shebley M, Jushchyshyn MI, Hollenberg PF. Selective pathways for the metabolism of phencyclidine by cytochrome p450 2b enzymes: identification of electrophilic metabolites, glutathione, and N-acetyl cysteine adducts. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 375-83. PMID 16326815 DOI: 10.1124/Dmd.105.007047  0.425
Show low-probability matches.